Vienna (pta014/14.05.2020/10:40) - May 14, 2020
The Management Board of Marinomed Biotech AG has decided to postpone the Annual General Meeting scheduled for June 19, 2020 in Vienna to September 17, 2020.
This decision was made in view of the current legal measures to contain the COVID-19 pandemic in Austria. The protection, safety and health of shareholders and employees is a top priority for Marinomed.
The Annual General Meeting will be convened at a later date in accordance with the legal requirements.
We kindly ask our shareholders for their understanding for the postponement.
About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna (Austria) and listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmological diseases. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Further information is available at: www.marinomed.com.
For further enquiries please contact:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331